Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache

Jones, J. Stephen; Pack, Steven; Chun, Eric

doi:10.1016/s0735-6757(96)90171-0

Cited by 94 publications

(132 citation statements)

References 12 publications

Supporting

Mentioning

127

Contrasting

Order By: Relevance

“…Prochlorperazine is used, alone or in combination, in different forms of headache. In particular, positive therapeutic results were obtained in migraine attacks or tension-type and vascular headache [14][15][16]. Prochlorperazine is able not only to abolish nausea and vomiting, but also to relief pain occurring during a migraine attack better than metoclopramide [17].…”

Section: Introductionmentioning

confidence: 99%

Prochlorperazine induces central antinociception mediated by the muscarinic system

Ghelardini

Galeotti

Uslenghi

et al. 2004

Pharmacological Research

View full text Add to dashboard Cite

The antinociceptive effect of the D 2 antagonist prochlorperazine was examined in the mouse hot-plate and abdominal constriction tests. Prochlorperazine (1-2 mg kg −1 s.c./i.p.) produced an increase of the pain threshold in the mouse hot-plate test. The antinociception produced by prochlorperazine was prevented by the D 2 selective agonist quinpirole, the unselective muscarinic antagonist atropine, the M 1 selective antagonist pirenzepine, and by the choline uptake inhibitor hemicholinium-3 hydrobromide (HC-3). Moreover, prochlorperazine antinociception was abolished by pretreatment with an aODN against the M 1 receptor subtype, administered at the dose of 2 nmol per single i.c.v. injection. By contrast the analgesic effect of prochlorperazine was not prevented by the opioid antagonist naloxone and the GABA B antagonist CGP-35348. Prochlorperazine also elicited a dose-dependent increase in ACh release from rat cerebral cortex. In the antinociceptive dose-range, prochlorperazine did not impair mouse performance evaluated by the rota-rod and hole-board tests. On the basis of the above data, it can be postulated that prochlorperazine exerted an antinociceptive effect mediated by a central cholinergic mechanism.

show abstract

Section: Introductionmentioning

confidence: 99%

Prochlorperazine induces central antinociception mediated by the muscarinic system

Ghelardini

Galeotti

Uslenghi

et al. 2004

Pharmacological Research

View full text Add to dashboard Cite

show abstract

“…Most compelling is the fact that D 2 -like receptor antagonists, such as prochlorperazine (Jones et al, 1996), metoclopramide (Colman et al, 2004), droperidol (Silberstein et al, 2003), and domperidone [5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one] (Waelkens, 1984), have been used to treat migraine, although none has an exclusively dopaminergic pharmacology. It has been shown that stimulation of dural (Akerman and Goadsby, 2005), coronary, renal, and mesenteric vascular D 2 -like receptors causes indirect vasodilatation by inhibition of sympathetic vasoconstrictor tone (Lahlou, 1998;Amenta et al, 2002).…”

mentioning

confidence: 99%

Comparison of the Effects of Central and Peripheral Dopamine Receptor Activation on Evoked Firing in the Trigeminocervical Complex

Charbit

Akerman²,

Goadsby³

2009

The Journal of Pharmacology and Experimental Therapeutics

View full text Add to dashboard Cite

Dopaminergic mechanisms have been suggested to play a role in migraine. Here, electrophysiological techniques were used to study the effects of intravenously administered centrally or peripherally active dopamine receptor agonists and antagonists on evoked firing in the trigeminocervical complex (TCC). After establishing baseline firing evoked by electrical stimulation of the dural middle meningeal artery (MMA) and mechanical noxious and innocuous stimulation of the ophthalmic dermatome, D 1 -or D 2 -like receptor agonists or antagonists were administered intravenously and the effect on firing was determined. In addition, with use of intravital microscopy, we monitored changes in dural vessel diameter in response to varying doses of D 1 -or D 2 -like receptor agonists to determine whether their effects were related to blood vessel caliber. The central -like receptor agonists cis-(Ϯ)-1-(aminomethyl)-3,4-dihydro-3-phenyl-1H-2-ben-zopyran-5,6-diol hydrochloride (A68930 hydrochloride) and dihydrexidine facilitated innocuous brush-evoked firing, with A68930 hydrochloride having the greatest effect. The data suggest that dopamine binding to peripheral D 1 -like receptors may play a role in peripheral sensitization, and that the inhibitory or excitatory effects seen with administration of dopamine receptor agonists are independent of blood vessel changes. In addition, these studies maintain that central D 2 -like receptors inhibit trigeminocervical neurons, and may provide insight into the conflicting literature on the role of dopamine and its receptors in migraine.

show abstract

“…Early placebo-controlled studies of intravenous (IV) prochlorperazine in the emergency room demonstrated a response rate of 88%, compared to 45% for placebo [11], and subsequent studies have shown that prochlorperazine is superior to metoclopramide, IV magnesium, and placebo [12,13]. In another emergency room study, IV prochlorperazine was more effective than ketorolac [14].…”

Section: Treatment Dopamine Antagonists In Acute Migrainementioning

confidence: 99%

Use of Dopamine Antagonists in Treatment of Migraine

Marmura

2011

Curr Treat Options Neurol

View full text Add to dashboard Cite

Dopamine antagonists are indicated for treatment of nausea or psychosis and have an established role in the treatment of migraine. Neuroleptics, including antipsychotics, act as antagonists at the dopamine D2 receptor type. These medications also have variable activity as antihistamines and anticholinergics, and they block alpha-adrenergic and some serotonin receptor types, but their actions on dopamine are likely the reason for their efficacy in treating nausea, psychosis, and acute migraine. Neuroleptics are first-line agents in the emergency room setting for migraine, especially for patients with nausea and vomiting. In the setting of a clear prodrome, antiemetics may prevent migraine when taken before an attack. They are also indicated in clinical situations such as patients who are pregnant or have contraindications to migraine-specific medications or NSAIDs. Recent developments suggest that dopamine is particularly important in chronic pain, and we most commonly use neuroleptic medications in the treatment of status migrainosus or medication-overuse headache. Clinicians may avoid dopamine antagonists because of unfamiliarity and a lack of large, controlled clinical trials. Their use requires special care to avoid adverse events such as sedation, akathisia or dystonic reactions, neuroleptic malignant syndrome, or movement disorders with long-term use. Some newer atypical neuroleptic agents appear promising for both acute and prophylactic migraine treatment with a lower risk of adverse events.

show abstract

Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache

Cited by 94 publications

References 12 publications

Prochlorperazine induces central antinociception mediated by the muscarinic system

Prochlorperazine induces central antinociception mediated by the muscarinic system

Comparison of the Effects of Central and Peripheral Dopamine Receptor Activation on Evoked Firing in the Trigeminocervical Complex

Use of Dopamine Antagonists in Treatment of Migraine

Contact Info

Product

Resources

About